Last reviewed · How we verify
Discontinue NA Treatment
Discontinue NA Treatment is a Small molecule drug developed by University Health Network, Toronto. It is currently FDA-approved.
At a glance
| Generic name | Discontinue NA Treatment |
|---|---|
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) (PHASE2)
- A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment (EARLY_PHASE1)
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
- Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants (PHASE2)
- Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B (EARLY_PHASE1)
- Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy (PHASE4)
- Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Discontinue NA Treatment CI brief — competitive landscape report
- Discontinue NA Treatment updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI
Frequently asked questions about Discontinue NA Treatment
What is Discontinue NA Treatment?
Discontinue NA Treatment is a Small molecule drug developed by University Health Network, Toronto.
Who makes Discontinue NA Treatment?
Discontinue NA Treatment is developed and marketed by University Health Network, Toronto (see full University Health Network, Toronto pipeline at /company/university-health-network-toronto).
What development phase is Discontinue NA Treatment in?
Discontinue NA Treatment is FDA-approved (marketed).